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Sm_ry Rats transplanted with the ascites hepatoma Yoshida AH-130 developed a severely progrssve
cahexa charactersed by marked alterais in protein and pid metabolsm. In parclar, high klvs of
serum triglycerides and free fatty acids were aiated with altered kvels and distribution of plasma
cholsterol, with increased total and very low-density lipoprotein-low-density lipoprotein (VLDL-LDL)
cholsterol and renhed high-density lipoprotein (HDL) coecsterol. The tumour cells showed high rates of
cholesterol synthesis and elevated content of free and esterified olesterol, whereas total cholsterol synthesis
was reduced in the host liver. To detmine whether these peturbations could be related to the elevation of
tumour necrosis factor a (TNF-a) previously shown in the AH-130 bearers (Tessitore L, Costelli P, Baccino
FM 1993, Br J Cancer, 67, 15-23), either anti-TNF polyckmal antibodies or non-immune IgGs we injected
daily after tumour tansplantaion. The anti-TNF treatment neither affected tumour growth nor prevented the
serum cholsterol changes, while attenuating the hypertriglyceridaemia and the deevated serm free fatty acid
levels. These data indte that TNF does not appear to be diectly involved in the altered cholsterol
metabolism in AH-130 hosts, thus supporting the view that choksterol metabolism and lpid metaboism are
regulated differently during tumour growth.
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In the past few years a large body of evidence has been
accumulated indicating a possible central role of choksterol
in the pathobiology of cancer. Alterations in the synthesis,
uptake and intracellular content of cholesterol have been
observed in a variety of experimental tumour models as well
as in different types of human neoplasms (Anderson et al.,
1981; Coleman and Lavietes, 1981; Yachnin et al., 1983; Dessi
et al., 1992a,b, 1994).
Choksterol perturbations also include change in lipo-
protein profiles in plasma compartment. In particular, a
definite decrease in high-density lipoprotein (HDL) klvels is a
consistent finding in both experimental rat tumours and
human neoplass (Dessi et at., 1991, 1992a,b, 1994) despite
the differences reported to exist between lipoprotein
metabolism in rodents and humans (Dietschy et al., 1993). In
contrast, changes in other serm lipid parameters, such as
total cholsterol and tnglyceride klvels, appear to vary and to
be speces specific and dependent on the histological type or
tumour grade (Dessi et al., 1991, 1992a,b, 1994). Therefore, it
is possible that the mechanistic basis for the altered HDL
levels is different from that responsible for the observed
changes in other serum lipid parameters. Admittedly, HDLs
play an important role in the transport of excess cholesterol
from extrahepatic tisues to the liver for reutilisation or
excretion into bile (reverse cholesterol transport). It is thus
conceivable that the observed low levels of HDL-cholesterol
may be related, at least in part, to a decrased choklsterol
efflux to HDL as a consequence of increased utilisation and
storage in actively proliferating tissues, such as neoplasms.
However, since precursor prticles of HDL are thought to
derive from lipolysis of triglyceride rich lipoproteins
(Eisenberg, 1984) and since a signcnt positive correlation
between plasma HDL cholesterol and lipoprotein lipase
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(LPL) activity in adipose tissue has also been reported
(Eisnberg, 1984), the possibility that low HDL cholesterol
concentrations observed during tumour growth may be
secondary to the decreased triglyceride clarance from
plasna, as a result of LPL inhibition, must also be con-
sidered
Tumour necrosis factor (rNF), a pleiotropic cytokine
primarily produced by activated macrophages in response to
invasve stimuli (Beutler and Cerami, 1988), has been fre-
quently reported as beng responsible for changes in lipid
metaboism which occur in association with infections and
tumours in a wide variety of species, including humans and
rats (Feingold et al., 1987, 1992; Harada et al., 1990). TNF
might affect plasm cholesterol, triglyceride and lipoprotein
levels by both inhibition of adipose LPL activity and/or
stimulation of hepatic lipogenesis (Feingold et al., 1992,
1993).
lipid metabolism in rats bearing ascites hepatoma Yoshida
AH-130 has been previously investigated in our laboratories.
This tumour causes in the host a rapid loss of body weight,
associated with mared perturbations of both protein (Tes-
sitore et al., 1987, 1993) and lipid metabolism (Dessi et al.,
1992a). Increased synthesis and progressive accumulation of
cholesterol were observed in AH-130 cells. During tumour
growth, rats developed changes in serm lipid concentrations
that included elevation of total cholesterol and triglycerides
as well as a sharp reduction of HDL-cholesterol. Concur-
rently, the plasma lvels of TNF were elevated, while the
activity of LPL in the white adipose tissue was decreased
(Tessitore et al., 1993; Carb6 et al., 1994).
Based on these results, the aim of the present study was to
investigate whether and to what extent TNF may mediate
chan in lipid metabolism in AH-130-bearing rats. The
results obtained using passive immunisation against TNF
seem to indicate that the TNF produced during tumour
growth altered triglycerde and free fatty acid metabolism,
yet was not involved in cholesterol metabolism perturbations.S Dss eti
Materiak an s
Anbnals and tumnours
The study was performed on male Wistar rats (Charles
River, Como, Italy), weighing about 150 g. They were main-
tained on a regular dark-icght cycle (light 8 am.-8 p.m.) and
free access to food (Piocioni, Brescia, Italy) and water. The
rats were divided into four groups, namely controls, tumour
hosts and tumour hosts treated with either non-immune IgGs
or anti-TNF antibody. The Yoshida ascites hepatoma cells
(approximately 10' cells per rat) were inoculated int-
raperitoneally (for details see Tessitore et al., 1987). The daily
food intake of all groups of animals was measured.
Treatments
Two groups of tumour hosts received daily a subcutaneous
injection of 25 mg kg-' body weight of a polyclonal goat
anti-murine TNF IgG preparation (anti-TNF) or of a non-
immune goat IgG preparation (IgGs), as previously described
(Bagby et al., 1991; Costelli et al., 1993). The treatment
started the day after transplantation and lasted 3 days.
Aninmls were killed on day 4 under light ether ana a
DNA synthesis
To measure DNA synthesis Yoshida AH-130 cells obtained
from the three groups of tumour hosts were incubated in the
presence of[pH]thymidine as previously reported (Dessi et al.,
1992a). Briefly, I x 10' tumour cells were placed into glass
tubes containing Krebs' bicarbonate buffer and lOiCi of
I'H]thymidine (25 Cimmol-', from New England Nuclear,
Boston, MA, USA) in an atmosphere of 95% oxygen-5%
carbon dioxide, and incubated at 3rC for 2 h. The cells were
then recovered on gss filters usng an automatic harvester
(Flow, Irvine, UK) and radioactivity counted in a liquid
scintillation spectrometer (Beckman, USA), using Ulima
Gold as scintillation fluid (Packard, Moriden, CT, USA).
Cholesterol and triglyceride synthesis
The rate of cholsterol and triglyceride synthesis was deter-
mined by measunng the in vitro incorporation of ['"acetate
in both liver and AH-130 tumour cells. Livers were cut into
thin sis (1 mm thick) and tumour cells processed as des-
cribed above. For the assay 500 mg of tissue shces or 2 x 107
tumour cells were placed in glass tubes containing Krebs'
bicarbonate buffer and incubated with 10pCi of ['4acetate
(New England, Nuclear, Boston, MA, USA, sp. ac.
45-60mCimmol[') for 2h at 3rC in an atmosphere of
95% oxygen-5% carbon dioxide. After incubation, the tissue
slces and the ceils were washed twice, homogenated, and
lipids exutacted with chloroform-methanol (2:1) according to
Folch et al. (1957). After evaporation of the solvent, the
lipids were dissolved in chloroform and neutral lipids were
separated by thin-layer .chromatography (DC-Alufolien
Kisegel 60, Merck, Darmstadt, Germany), using the solvent
system ptaisopropy r-foc acid (60:40:2, v/v/
v). The bands corresponding to free and esterified cholesterol
and triglycerides were then visualsed using iodine vapour
and scraped into counting vials to detect the incorporation of
['4CJacetate (Bowman and Wolf, 1962; Van Handel and
Zilvrsmit, 1968).
Separation oflipoproteins by high-performance liquid
chromatography (HPLC)
Serum lipoproteins were separated by HPLC according to
Okazaky et al. (1980). The analyses were carried out on a
Series 4 Perfin-Elmer liquid chromatograph equipped with
LC-85B Perkin-Elmer variable wavelngth UV detector and a
H Series 3396 Hewlett-Packard integrator. An aliquot of
10 11 of serum was injected and sodium chloride (pH 6.96;
0.15 M) was used as eluant. The columns were gel permeation
chromatography (GPC) columns filled with mirospheres of
hydrophilic polYmers with an aqueous support based on a
chemically modified silica (TSK GEL, Toyo Soda, Tokyo).
Each column was 600 x 7.5 mm i.d. For better resolution of
lipoprotein subfraction peaks, a combination of GPC col-
umns (G5000PW + G3000SW x 2) was used. To increase the
lifesPan of the columns a guard column was inserted. The
columns were balanced with very low-density lipoprotein
(VLDL), low-density lipoprotein (LDL), HDL2 and HDL3
standard prepared by ultracentrifugation according to the
method of Havel et al. (1955). Proteins in VLDL, LDL,
HDL2 and HDL3 subfractions were monitored by absorbance
at 280 nm.
Analyticalprocedures
To determine free and esterified cholesterol as well as trigly-
ceride contents, total lipids were extracted as described
above. The two cholesterol moietes were measured as
directed by Bowman and Wolf (1962), using cholesterol and
cholesterol palmitate (Sigma, St Louis, MO, USA) as stan-
dards, while triglyceride content was evaluated by the
method ofVan Handel and Zilversmit (1968), with triolein as
the worling standard.
DNA content was measured by the method of Boer (1975)
and protein that of Lowry et al. (1951), using herring sperm
DNA and bovine serum albumin as working standards
IrePetively.
Cholsterol, triglyceride, free fatty acid and phospholipid
concentrations in plasma and ascitic fluid were estimated
using commerially available kits (Boheringer, Mann.eim,
Germany). VLDL and LDL were isolated by precipitations
with a mixture ofphosphotungstic acid and magnesium ions.
After standing for 10 min at room temper e the mixtures
were centrifuged at 10000g for 10min, the supernatant
containing the HDL fraction was removed and the levels of
choleterol, triglyceride and phospholipid were determined.
The precpitate containing the VLDL-LDL fraction was dis-
solved in 0.15 M sodium chloride and the cholsterol, trigly-
cerides and phospholipids were assayed as above.
Statistical analysis
Significance ofthe differences was caculated by the Student's
t-test.
Rc6
The ascites hepatoma Yoshida AH-130 caused a loss ofbody
weight in tumour hosts, in assocation with the presene of
detctable levels in circulating TNF. A decrease in daily food
intake was also observed in tumour-bearing rats (Table I).
The results are in agreement with our previous studies which
have d onstrated that ascites hepatoma AH-130 causes in
the rat host a pd and progre loss of body weight, a
progressivedecline of food intake, skeletal muscle waste and
ipid depletion (Costelli et al., 1993; Carb6 et al., 1994). The
anti-TNF treatment effectively neuralsed circulating TNF,
while neither the anti-TNF antibodies nor non-immune IgGs
modified tumour growth, body weight loss and food intake
dedine (Table I).
The hepatic synthesis of total choksterol and triglyrides
is shown in Table HI. The synthesis of total choleterol was
reduced during tumour growth, while no changes were
obsrved for triglycides, in keeping with previous obser-
vations (Dessi et al., 1992a). The anti-TNF treatment did not
modify either parameter.
High synthesis rates for cholesterol, both free and
eterified, and for triglycerides have been observed in the
AH-130 cells (see Dessi et al., 1992a) and were not modified
by the anti-TNF treatment (Table III). Consitently, total
and free cholesterol and tiglyceride levels in tumour cells
were not affected by the treatment (Table IV). Moreover,
0
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Table I Body weight, food intake, tumour growth, and plasma TNF in AH-130 tumour bearing
rats
[3HJThyMidne
Animals and Body weight Food intake Twuour cells incorporation TNF
treatment n (g) (g) (x 1it) (d.pm. lig DNA) (pgml-')
Controls 4 147 ±? 22+2a 2 _ ND
AH-130 hosts
None 9 125 9gb 16 lb 1458± 2O8 6198 ± 52la 88 ± 4a
IgGs 5 117 2b 15 lb 1678 ± 261a 5946 ± 499a 80± 7a
Anti-TNF 5 116 3b 15 lb 1705 ± 401a 6578 ± 320a ND
Values are mean ± s.e.m. Body weight in AH-130 hosts is exchlsive of tumour. ND, not detectable.
-bMeans with different kl s are significantly different (P<0.01).
Table H Cholesterol and tnglyceride synthesis in liver of AH-130
tumour-bearing rats
["C]Acetate ["C]Acetate
incorporated into incorporated into
Aninals and choksterol triglycerides
treatnent n (cpm 10)g-) bier) (c.pin 1( -I liver)
Controls 4 1857±85 1445 244'
AH-1330 hosts
None 9 748+ 103b 1047 64'
IgGs 5 1191 + 164b 1413_267a
Anti-TNF 5 1089 137b 1414 437P
Values are mean ± s.e.m. "Means with different ktters are
significantly different (P<0.01).
anti-TNF administration did not change the intracellular
content of phospholipids or protein (Table IV).
The lipid and protein content of whole serum collected
from control and tumour-bearing rats receiving anti-TNF or
not is presented in Table V. While plasma protein is
dreased nearly 20% in AH-130-bearing animals, the lvels
of all lipid classes, except phospholiids are elevated, parti-
cularly free fatty acids and triglycerides. Trigykeride and free
fatty acid levels were reduced, at least in part, by anti-TNF
administration. Likewise, the anti-TNF treant prevented
the decrease in serum protein concentration, which is consis-
tent with its effectiveness in preventing tissue protein hyper-
catabolism (Costelli et al., 1993). By contrast the above
parameters were not modified when the animals were given
the non-immune IgGs (Table V).
In the untreated tumour hosts both the protein and lipid
constituents of the HDL lipoprotein fraction were decreased,
with the exception of triglycerides, whose levels inreased 3-
4-fold with respect to controls (Table VI; see Dessi et al.,
1992a). The anti-TNF treatment was able to correct the
reduced protein content only (Table VI). By contrast, all the
constituents were inreased in the VLDL-LDL fraction of
untreated AH-130 bearers with respect to controls Anti-TNF
antibodie reduced, at least in part, the elevation of trigly-
cenides (Table VII). Non-immune IgGs genrally did not
affect the parameers analysed in both the HDL and
VLDL-LDL fractions, with the exception of triglycerides in
the latter (Table VII).
Consistent with the results obtained using precipitation
methods, the analysis of plasma lipoproteins by HPLC
revaled an elevation of VLDL-LDL in host rats compared
with controls (Figure la and b). In contrast HDL2, normally
the main lipoprotein subfraction in rat serum was strongly
reduced. (Figue lb). An increase in the HDL3 subfraction
was also evident in AH-130 tumour-bearing rats (Figure lb).
Anti-TNF treatment was able to reduce both VLDL and
LDL fraction in AH-130-bearing rats, while in these animals
HDL2 remains below the normal values (Figure ld). IgGs did
not affect greatly lipoprotein profiles observed in tumour-
bearing rats (Figure lc).
Fmally, the anti-TNF treatment did not modify the lipid
and protein composition in the ascitic fluid (data not shown).
Previous studies by our laboratories (Dessi et al., 1992a) as
well as the present one have revealed that rats bearing ascites
hepatoma AH-130 are characterised by a specific pattern of
lipid metabolism. Cholesterol synthesis and content were
high in AH-130 cells, triglycerides and total cholesterol in-
creased in the host plasma, while esterifed cholesterol was
decreased to about 50% compared with control values.
Analysis of plasma lipoproteins revealed an elevation of
VLDL and LDL in host rats compared with control animals,
with more than a 3-fold increase in both lipid and protein
content. In contrast HDL, in particular the HDL2 subfrac-
tion, was reduced. These alterations were associated with
marked perturbations in the hormonal homeostasis and
presence of detectable levels of circulating TNF (Tessitore et
al., 1993).
Changes in lipid metabolism are a common feature during
neoplastic growth, both in humans and in different experi-
mental model systems (Clark and Crain, 1986; Dessi et al.,
1986, 1989, 1992a,b, 1994). However, the mechanisms under-
lying these changes are stfill unclear and complicated by the
fact that the metabolic alterations are species specific and
dependent on the histological type or the degree of malig-
nancy.
In this report, our results on serum cholesterol and lipo-
protein levels in tumour-bearing rats were similar to those
previously observed by other investigators in rats and mice
(Kannan and Baker, 1977; Clark and Crain, 1986), but in
contrast with those reported in humans (Rossner and Wall-
gren, 1984; Vitols et al., 1985; Bani et al., 1986; Reverter et
al., 1988; Dessi et al., 1991, 1992b, 1994). In particular,
normal or decreased serum cholsterol levels were observed
in cancer patients, while triglyceridaemia appears variable,
dependent on the type of tumours and age of appearance.
Nevertheless, a decrease in crculating HDL levels is found
in virtually all neoplastic and inflammatory diseases studied
in both rodents and humans (Dessi et al., 1986, 1989, 1991,
1992a,b, 1994; Feingold et al., 1993) suggesting that the
mechanisms underlying changes in total cholesterolaemia and
triglycerilaemia are presumably different from those respon-
sible for lowering HDL levels.
Based on our data, two mechanisms can be considered to
explain the increase in circulating lipids in AH-130 hosts.
First, an increased moblisation of lipids from fat depots, as
evidenced by the loss of body weight and the increase in
serum free fatty acids. Second, a decrease in the clarance of
VLDL as evidenced by the decrease in LPL activity in
adipose tissue previously observed in this type of tumour
(Carbo et al., 1994). Under our experimental conditions, it is
unlikely that diet and endogenous biosynthesis can be res-
ponsible for the observed hyperlipidaemia in that both
hepatic lipid synthesis and food intake, the two main sources
of plasma lipids in the body, were normal or decreased in
tumour-bearing rats.
TNF, a pleiotropic cytokine, is primarily produced by
activated macrophages in response to invasive stiuli
(Beutler and Cerami, 1988). As for lipid homeostasis, TNF
has been shown to activate peripheral lipolysis and hepaticAnti-TW ad rpid niaabnlc In AH43D4bwng rat
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Table HII Cholesterol and tnglycenrde synthesis in AH-130 cells
['4C]Acetate incorporated into cholesterol ["C]Acetate incorporated
Free Esterified into triglycerides
Treatment n (c.p.mLg-' DNA) (cp.m. ng' DNA (c.p.m. ng-' DNA)
None 9 4.43 ± 1.14a 24.51 ±6.W4a 29.90 ± 3.99a
IgGs 5 3.37 ± 0.83a 22.14 ± 4.84a 22.25 ± 5.21l
Anti-TNF 5 3.00 ± 0.20" 18.13 ± 4.97a 26.62 ± 4,59a
Values are mean ± s.e.m. aMeans with the same letter are not significantly different.
Table IV Cholesterol. lipid and protein content in AH-130 cells
Cholesterol
Treatment n Total Free Triglycerides Phospholipids Proteins
None 9 146 ± 13a 56.2 ± 8.4" 254 ± 13a 184 ± 18" 7.38 ± 1.03"
IgGs 5 128 ± 17a 43.7 3,4a 209 ± 25a 182 ± 14a 7.40 ± 0.32a
Anti-TNF 5 115 1la 59.5±2.2a 222± 18a 199±28a 8.37 1.11la
Values are mean ± s.e.m. expressed as jig 10- cells except for proteins (mg 10- cells). aMeans with the
same letter are not significantly different.
Table V Cholesterol. lipid and protein content in serum of AH-130 tumour-bearing rats
4nimals and Total cholesterol Triglycerides Phospholipids Free fatty acid Proteins
treatment n (mg dl-' (mg dl_ I (mg dl 'I (pequiv. l- (mgml-,)
Controls 4 85.3 ± 7.9a 1001 ± lla 63.6 ± 5.1a 834 ± 63.7a 68 4 ± 2.5a
AH-130 hosts
None 9 99.2 ± 3.5a 334 ± 38b 70.8 ± 5.6" 1852 ± 80.2k 56.4 ± 2.8b
l_gGs 5 112.0 ± 7.1" 397 ± 23b 79.6 ± 4.5" 1984 ± 99.0b 57.2 ± 3.8b
Anti-TNF 5 102.8 ± 6.4" 213 ± 23b-c 67.0 ± 6.6a 1263 + 92.8b 69.4 ± 5.2c
Values are mean ± s.e.m. a,bc'Means with different letters are significantly different (bp< 0.05 vs controls.
'P<0.05 vs untreated AH-130 hosts).
Table VI Cholesterol, lipid and protein composition of HDL lipoproteins in AH-130
tumour-bearing rats
Animals and Cholesterol Triglycerides Phospholipids Proteins
treatments n (mg dl-I) (mg dl- ) (mg dl-' (mg ml-,
Controls 4 55.8 ± 2.7a 3.7 ± 0.7a 28.8 ± 5.1" 56.4 ± 3.9"
AH-130 hosts
None 9 39.9 ± 2.7b 15.5 ± .lb 17.6 ± 1.7c 40.0 ± 3.8c
IgGs 5 38.8 ± 6.0b 19.7 ± 0.7b 14.6 ± 2.8c 35.9 ± 4.0'
Anti-TNF 5 42.8 ± 4QOb 14.4 ± 1.7b 15.8 ± 3.Oc 53.8 ± 5.0"
Values are mean ± s.e.m. abhdMeans with different letters are significantly different (bP<0.01 cP<0(05 vs controls; dp<O.05 vs untreated AH-130 hosts).
Table VII Cholesterol, lipid and protein composition of VLDL-LDL lipoproteins in
AH-130 tumour-bearing rats
Animals and Cholesterol Triglycerides Phospholipids Proteins
treatments n (mg dl- (mg dl-' (mg dl-' (mg ml-')
Controls 4 21.6 ± 1.3" 85.2 ± 8.3" 10.4 ± 0.9a 5.4 ± 0.3a
AH-130 hosts
None 9 52.7 ± 3.5b 247.0 ± 33.8b 41.1 ± 3.7b 9.5 ± 0.5b
IgGs 5 37.5 ± 2.3c 354.0 ± 14.2bd 52.5 2.5b 11.9± 2.2b
Anti-TNF 5 41.0 ± 2.2c 177.0 ± 23.3c-d 50.1 ± 44b 10.5 ± 09b
Values are mean ± s.e.m. a.bcdMeans with different letters are significantly different (bp<0.0P1, Cp<0.05 vs controls; dp<0,05 vs untreated AH-130 hosts).
lipogenesis, resulting in increased concentrations of cir-
culating lipids (Feingold and Grunfeld, 1987; Starnes et al..
1988; Evans et al., 1989; Grunfeld et al., 1989). In the
adipose tissue this cytokine inhibits the synthesis of LPL
(Kawakami et al., 1982) as well as the synthesis of acetyl-
CoA carboxylase (Pape and Kim. 1988), fatty acid synthetase
(Pekala et al., 1983), fatty acid binding protein and glycerol
phosphate dehydrogenase (Torti et al., 1985), all ofwhich are
involved in lipid synthesis. TNF also stimulates triglyceride
degradation in adipocytes by activating the hormone-
sensitive lipase (Pekala et al.. 1984).
In vivo administation of this cytokine results in decreased
LPL activity in the adipose tissue (Semb et al., 1987; Evans
and Williamson, 1988). In a recent study by Ettinger et al.
(1990), total plasma cholesterol was reported to be decreased
in monkeys treated with TNF (or LPS), due to a reduction in
both LDL and HDL fractions and in association with low
lecithin-cholesterol acyltransferase activity; moreover, plasma
triglycerides were increased, as commonly observed after
TNF administration. By contrast, other authors have
observed increased serum cholesterol levels after TNF
administration (Feingold and Grunfeld, 1987).
These observations support the conclusion that TNF may
be involved in the alterations of lipid metabolism that affectAii-TNF d d I uIs I AH-1304bwiq rib
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Figwe 1 Separation by HPLC of serum lipoproteins in AH-130 tumour-bearing rats. Peaks: 1, VLDL; 2, LDL; 3, HDL; 4, HDL3;
5, other serum proteins. (a) Controls. (b) AH-130 hosts. (c) AH-130 hosts + IgGs. (d) AH-130 hosts + anti-TNF.
the AH-130 tumour bearers (Carbo et al., 1994). However,
treatment with anti-TNF only partially corrected tumour-
induced perturbations of lipid metabolism. In particular, trig-
lyceridaemia and free fatty acid levels were reduced, while
anti-TNF treatment did not affect total cholesterolaemia and
HDL levels.
Cell proliferation, either normal or neoplastic, is com-
monly associated with altered cholesterol metabolism, and in
particular with decreased plasma HDL-cholesterol levels
(Dessi et al., 1986, 1989, 1992b). It has been proposed that
this reduction results from a decrease in the release of
cholesterol from proliferating cells to HDL (Daniels et al.,
1987). Exogenous cholesterol and cell growth rate modulate
the activity of specific HDL receptors; the binding with HDL
promotes selective removal of excess cholesterol from the
intracellular pool (Oram et al., 1987). It has been shown that
both HDL-mediated efflux and HDL receptor activity are
down-regulated in actively proliferating cells (Bierman et al.,
1989), likely resulting in the reduction of HDL-cholesterol
plasma levels.
In the present paper we demonstrate that the anti-TNF
treatment is unable to either modify the growth rate of the
AH-130 hepatoma or to prevent the decrease in plasma
HDL-cholesterol, further supporting the existence of a close
relationship between these two parameters.
On the whole, these observations suggest that the hyper-
triglyceridaemia and the increase of VLDL and LDL, and
the increase of HDL metabolism in rats bearing the AH-130
tumour are regulated, at least in part, by different
mechanisms. Decreased LPL activity mediated by TNF could
well account for the former. By contrast, TNF does not
appear to be directly involved in the perturbations of HDL
metabolism, which seem to be strictly related to tumour
proliferation rates.
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